Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.52
-0.1350-8.18%
Volume:2.11M
Turnover:3.35M
Market Cap:641.88M
PE:-10.93
High:1.66
Open:1.66
Low:1.50
Close:1.65
52wk High:1.83
52wk Low:0.3600
Shares:423.68M
Float Shares:418.00M
Volume Ratio:1.16
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1387
EPS(LYR):-0.1387
ROE:-39.72%
ROA:-12.65%
PB:5.97
PE(LYR):-10.93

Loading ...

Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026

Reuters
·
Mar 24

Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 23

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
Mar 23

Lexicon, Novo Nordisk announce initiation of LX9851 study

TIPRANKS
·
Mar 23

Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851

Reuters
·
Mar 23

Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027

THOMSON REUTERS
·
Mar 23

Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851

THOMSON REUTERS
·
Mar 23

Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments

THOMSON REUTERS
·
Mar 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Mar 13

Lexicon announces results from post hoc analysis on data of sotagliflozin

TIPRANKS
·
Mar 11

Lexicon to present sotagliflozin kidney function analysis at ATTD conference

Reuters
·
Mar 11

Lexicon Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 10

Lexicon price target raised to $2.30 from $2.10 at Citi

TIPRANKS
·
Mar 10

Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones

TIPRANKS
·
Mar 10

Leerink Partners Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
Mar 06

Lexicon Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 06

Lexicon price target raised to $6 from $4 at H.C. Wainwright

TIPRANKS
·
Mar 06

Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend

Reuters
·
Mar 05

Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate

Benzinga
·
Mar 05

BRIEF-Lexicon Pharmaceuticals Q4 EPS USD -0.04

Reuters
·
Mar 05